Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Liminal BioSciences Inc. PFSCF


Primary Symbol: LMNL

Liminal BioSciences is a biopharmaceutical company focused on the discovery and development of novel, small molecule drug candidates for the treatment of patients suffering from fibrotic or inflammatory diseases that have a high unmet medical need. Liminal BioSciences operates on an integrated basis from our talent hubs in Laval, Quebec, Canada, and Cambridge, UK. Our common shares are listed for trading on the Nasdaq Global Market.


NDAQ:LMNL - Post by User

Bullboard Posts
Post by Transit77on Apr 23, 2019 11:06pm
278 Views
Post# 29662824

Ok gentlemen we are good : )

Ok gentlemen we are good : )Rights Offering Concurrent with the announcement of the transactions described above, on April 15, 2019 , the Corporation announced the launch of a rights offering to the registered holders of Common Shares (the "Rights Offering"). Under the Rights Offering, registered holders will be eligible to acquire, for each Common Share held by such registered holder, one right to purchase twenty (20) Common Shares at the Transaction Price. The maximum number of Common Shares issuable upon the exercise of rights will be the quotient of $75 million and the Transaction Price, with any exercise of rights in excess of this limit subject to proration across all exercising holders. It is not SALP's current expectation or intention to exercise its rights in the Rights Offering and purchase additional Common Shares, further enabling retail and existing shareholders of the Corporation to participate in the transactions at the same price as SALP and the third party investor that led the Private Placement.
Read more at https://stockhouse.com/companies/bullboard?symbol=t.pli&postid=29662788#5QufPPc3FDtvazj8.99
Bullboard Posts